Andrew Clark

818 total citations
41 papers, 460 citations indexed

About

Andrew Clark is a scholar working on Infectious Diseases, Virology and Epidemiology. According to data from OpenAlex, Andrew Clark has authored 41 papers receiving a total of 460 indexed citations (citations by other indexed papers that have themselves been cited), including 28 papers in Infectious Diseases, 22 papers in Virology and 7 papers in Epidemiology. Recurrent topics in Andrew Clark's work include HIV/AIDS drug development and treatment (24 papers), HIV Research and Treatment (22 papers) and HIV/AIDS Research and Interventions (19 papers). Andrew Clark is often cited by papers focused on HIV/AIDS drug development and treatment (24 papers), HIV Research and Treatment (22 papers) and HIV/AIDS Research and Interventions (19 papers). Andrew Clark collaborates with scholars based in United Kingdom, United States and France. Andrew Clark's co-authors include Jeanne Katz, Sheila Peace, Caroline Holland, David E. Swayne, Kateri Bertran, Sarah Flèche, Nattavudh Powdthavee, Abel Brodeur, Manoli Vourvahis and Yong‐Kuk Kwon and has published in prestigious journals such as SHILAP Revista de lepidopterología, Antimicrobial Agents and Chemotherapy and Frontiers in Immunology.

In The Last Decade

Andrew Clark

34 papers receiving 426 citations

Peers

Countries citing papers authored by Andrew Clark

Since Specialization

Citations

This map shows the geographic impact of Andrew Clark's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Andrew Clark with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Andrew Clark more than expected).

Fields of papers citing papers by Andrew Clark

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Andrew Clark. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Andrew Clark. The network helps show where Andrew Clark may publish in the future.

Co-authorship network of co-authors of Andrew Clark

This figure shows the co-authorship network connecting the top 25 collaborators of Andrew Clark. A scholar is included among the top collaborators of Andrew Clark based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Andrew Clark. Andrew Clark is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

#	Work	Indexed citations
1	Cost-effectiveness of introducing a maternal vaccine or long-acting monoclonal antibody to prevent infant respiratory syncytial virus disease in Nepal 2025 ·Journal of Global Health ·(unknown), (unknown), (unknown), (unknown), Clint Pecenka, (unknown), Louis Bont, Andrew Clark, (unknown)	0
2	New Approaches to Investigate Novel Agents in Ewing Sarcoma: A Report From the Children's Oncology Group Bone Tumor Committee 2025 ·Pediatric Blood & Cancer ·(unknown), (unknown), Christine M. Heske, Filemon S. Dela Cruz, Sarah Burkhead Whittle, Sarah Cohen‐Gogo, Anderson B. Collier, Ajay Gupta, Joyce E. Ohm, Andrew Clark, Alice Soragni, Elizabeth R. Lawlor, Bhuvana A. Setty, Patrick J. Grohar, Katherine A. Janeway, Damon R. Reed, Emily K. Slotkin, Kelly M. Bailey	0
3	The sensitivity of HIV-1 gp120 polymorphs to inhibition by temsavir correlates to temsavir binding on-rate 2024 ·Antiviral Research ·(unknown), Margaret Gartland, Jagadish Beloor, (unknown), Jana Wolf, Eugene L. Stewart, Andrew Clark, Allan R. Tenorio, (unknown)	0
4	Long-term safety and impact of immune recovery in heavily treatment-experienced adults receiving fostemsavir for up to 5 years in the phase 3 BRIGHTE study 2024 ·Frontiers in Immunology ·Josep M. Llibre, Judith A. Aberg, Sharon Walmsley, Juan D. Vélez, Carlos Zala, Brenda Crabtree‐Ramírez, (unknown), (unknown), Andrew Clark, Allan R. Tenorio, Amy Pierce, (unknown), Bo Li, (unknown), (unknown), (unknown)	1
5	Inflammatory Biomarker Reduction With Fostemsavir Over 96 Weeks in Heavily Treatment-Experienced Adults With Multidrug-Resistant HIV-1 in the BRIGHTE Study 2024 ·Open Forum Infectious Diseases ·Andrew Clark, (unknown), (unknown), Amy Pierce, José Castillo‐Mancilla, (unknown), (unknown), Allan R. Tenorio	1
6	Immunological and virological response to fostemsavir in routine US clinical care: An OPERA cohort study 2024 ·HIV Medicine ·(unknown), Laurence Brunet, (unknown), Gerald Pierone, Brooke Levis, Jennifer S Fusco, Cassidy Henegar, Vani Vannappagari, Andrew Clark, Gregory Fusco	0
7	Efficacy and safety of switching to dolutegravir/lamivudine in virologically suppressed people with HIV-1 aged ≥ 50 years: week 48 pooled results from the TANGO and SALSA studies 2024 ·AIDS Research and Therapy ·Sharon Walmsley, Don Smith, Miguel Górgolas, Pedro Cahn, Thomas A. Lutz, Karine Lacombe, Princy Kumar, Brian Wynne, Richard Grove, (unknown), (unknown), Chinyere Okoli, (unknown), (unknown), Andrew Clark, Mounir Ait‐Khaled	1
8	Chikungunya seroprevalence, force of infection, and prevalence of chronic disability after infection in endemic and epidemic settings: a systematic review, meta-analysis, and modelling study 2024 ·The Lancet Infectious Diseases ·(unknown), Megan Auzenbergs, Hannah Clapham, (unknown), Jong‐Hoon Kim, Henrik Salje, Christopher G. Taylor, Ahyoung Lim, Andrew Clark, W. John Edmunds, Sushant Sahastrabuddhe, Oliver J. Brady, Kaja Abbas	29
9	Patient Characteristics, Treatment Patterns, and Outcomes for Patients With Renal Cell Carcinoma in England: A Retrospective Cohort Study 2024 ·Clinical Genitourinary Cancer ·Prantik Das, Alison Booth, Robert M. Donaldson, (unknown), Beth Nordstrom, Robert Carroll, (unknown), Andrew Clark, (unknown)	2
10	Heavily treatment-experienced people living with HIV in the OPERA® cohort: population characteristics and clinical outcomes 2023 ·BMC Infectious Diseases ·(unknown), Jennifer S Fusco, Cassidy Henegar, Vani Vannappagari, Andrew Clark, Laurence Brunet, (unknown), Gerald Pierone, Gregory Fusco	5
11	Week 240 Efficacy and Safety of Fostemsavir Plus Optimized Background Therapy in Heavily Treatment-Experienced Adults with HIV-1 2023 ·Infectious Diseases and Therapy ·Judith A. Aberg, (unknown), (unknown), (unknown), (unknown), Christine Katlama, Shannon Schrader, Joseph J. Eron, Princy Kumar, Eduardo Sprinz, Margaret Gartland, (unknown), Andrew Clark, Amy Pierce, Max Lataillade, Allan R. Tenorio	7
12	Comparative Efficacy and Safety of Fostemsavir in Heavily Treatment-Experienced People With HIV-1 2022 ·Clinical Therapeutics ·Sarah‐Jane Anderson, (unknown), (unknown), (unknown), Andrew Clark, (unknown), Melanie Schroeder	2
13	Direct and indirect costs of acute diarrhea in children under five years of age in Indonesia: Health facilities and community survey 2021 ·The Lancet Regional Health - Western Pacific ·Jarir At Thobari, Sutarman Sutarman, (unknown), Emma Watts, Natalie Carvalho, Frédéric Debellut, Andrew Clark, Yati Soenarto, Julie E. Bines	18
14	Dolutegravir-based regimens in treatment-naive and treatment-experienced aging populations: analyses of 6 phase III clinical trials 2021 ·SHILAP Revista de lepidopterología ·(unknown), (unknown), (unknown), M. van der Kolk, (unknown), Richard Grove, Brian Wynne, Jean van Wyk, Andrew Clark	7
15	Covid-19, Lockdowns and Well-Being: Evidence from Google Trends 2020 ·SSRN Electronic Journal ·Abel Brodeur, Andrew Clark, Sarah Flèche, Nattavudh Powdthavee	41
16	Towards a Maraviroc long-acting injectable nanoformulation 2018 ·European Journal of Pharmaceutics and Biopharmaceutics ·Lee Tatham, (unknown), (unknown), Marco Siccardi, Trevor P. Scott, Manoli Vourvahis, Andrew Clark, Steve P. Rannard, Andrew Owen	21
17	Mitigation strategies to reduce the generation and transmission of airborne highly pathogenic avian influenza virus particles during processing of infected poultry 2018 ·International Journal of Hygiene and Environmental Health ·Kateri Bertran, Andrew Clark, David E. Swayne	9
18	Improving maraviroc oral bioavailability by formation of solid drug nanoparticles 2018 ·European Journal of Pharmaceutics and Biopharmaceutics ·(unknown), Lee Tatham, Marco Siccardi, Trevor P. Scott, Manoli Vourvahis, Andrew Clark, Steve P. Rannard, Andrew Owen	20
19	Effectiveness of current and future regimens for treating genotype 3 hepatitis C virus infection: a large-scale systematic review 2017 ·BMC Infectious Diseases ·(unknown), Andrew Clark, Nathan R. Hill, Geoffrey Dusheiko	23
20	Social interactions in urban public places 2007 ·Open Research Online (The Open University) ·Caroline Holland, Andrew Clark, Jeanne Katz, Sheila Peace	100

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact